Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 20.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,539 shares of the specialty pharmaceutical company’s stock after selling 33,467 shares during the period. Wedge Capital Management L L P NC’s holdings in Jazz Pharmaceuticals were worth $30,492,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $38,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $61,000. Westpac Banking Corp purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $51,000. Leonteq Securities AG purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at about $50,000. Finally, Harbor Investment Advisory LLC boosted its holdings in Jazz Pharmaceuticals by 349.2% in the 2nd quarter. Harbor Investment Advisory LLC now owns 292 shares of the specialty pharmaceutical company’s stock worth $70,000 after buying an additional 227 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at approximately $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 19,098 shares of company stock worth $4,649,786. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Stock Down 3.3%

Shares of NASDAQ JAZZ opened at $247.98 on Wednesday. The company has a 50 day simple moving average of $242.20 and a 200-day simple moving average of $210.98. The company has a market capitalization of $16.10 billion, a P/E ratio of 17.10, a P/E/G ratio of 0.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. Jazz Pharmaceuticals PLC has a 1 year low of $110.26 and a 1 year high of $265.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company’s revenue was up 15.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($8.25) earnings per share. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 21.62 earnings per share for the current year.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz will acquire Actio for $820 million upfront, with up to $500 million in additional contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1-positive epilepsy, a rare inherited condition with no approved treatments. The acquisition reinforces Jazz’s existing neuroscience strategy and could provide a valuable future growth asset if the drug succeeds in clinical development. Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
• Positive Sentiment: Analysts at RBC described the Actio acquisition as strategically sensible, citing strong synergies with Jazz’s rare-disease capabilities, development expertise and commercial infrastructure. The transaction could diversify Jazz’s pipeline beyond currently marketed therapies and strengthen its position in epilepsy. Jazz Pharmaceuticals’ Actio Acquisition Makes Sense, Has Good Synergy, RBC Says
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day short-interest ratio. Because the data shows no measurable short position and includes an invalid percentage-change calculation, it provides little useful information about current trading sentiment. Jazz Pharmaceuticals Short Interest Data
• Negative Sentiment: The acquisition requires a substantial upfront cash commitment for an experimental, clinical-stage asset, while the full value could reach $1.32 billion. Investors face clinical-development, regulatory and commercialization risks, and ABS-1230 may not generate near-term revenue. Those risks appear to be offsetting enthusiasm about the strategic fit and contributing to the stock’s weaker performance. Jazz Bets on Epilepsy Treatment With Up to $1.32 Billion Deal for Actio

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on JAZZ shares. TD Cowen boosted their price objective on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Leerink Partners increased their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Morgan Stanley lifted their target price on shares of Jazz Pharmaceuticals from $280.00 to $283.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $272.89.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.